Products for Research Use Only
RegisterLogin

ERBB2 Antibody

CAT: 0013-GTR18117804Size: 0.1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR18117804Size:0.1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ERBB2 Antibody
Product Name Alternative
NEU; NGL; HER2; TKR1; CD340; HER-2; VSCN2; MLN 19; c-ERB2; c-ERB-2; HER-2/neu
UniProt
P04626
Immunogen
Humanized / ERBB2 (HER2, Tyrosine kinase-type cell surface receptor HER2, MLN19, Metastatic lymph node gene 19 protein, ERBB2, Proto-oncogene Neu, p185erbB2, CD_antigen=CD340, Proto-oncogene c-ErbB-2, MLN 19, NEU, Receptor tyrosine-protein kinase erbB-2, NGL) [Homo sapiens]
Target
ERBB2
Clonality
Recombinant
Conjugation
Unconjugated
Source
CHO cells
Field of Research
Signal Transduction
Purification
>95%
Concentration
Batch dependent
Purity
>95%
Storage Conditions
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at +4°C short term (1-2 weeks) . Store at -20 °C 12 months. Store at -80°C long term.
Notes
For research use only.
Applications Notes
Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes are observed in vitro as a consequence of Trastuzumab binding to HER2-overexpressing cells. Interaction of Trastuzumab with the human immune system via its human immunoglobulin G1 Fc domain may potentiate its antitumor activities. in vitro studies demonstrate that Trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets[1]. Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane portion of the extracellular domain of the HER2 receptor and that prevent the activation of its intracellular tyrosine kinase. Trastuzumab recruits immune effector cells that are responsible for antibody-dependent cytotoxicity[2]. The presence of Trastuzumab IgG significantly increases killing of all breast cancer cell lines. The ADCC activity of PBMCs evoked by Trastuzumab is equally strong against Trastuzumab-sensitive (SKBR-3) or Trastuzumab-resistant (JIMT-1) breast cancer cells, with dose-dependent cell death reaching 50–60% killing at an effector/target ratio of 60:1[3].
NCBI Accession Number
P04626
Preservative
PBS buffer pH 7.5
Isotype
Human IgG1

Related Products

CatalogName
GTR17690621ErbB 2/ERBB2 Rabbit Polyclonal Antibody
GTR18224312ERBB2/HER2 Antibody
GTR18222120ERBB2/HER2 Antibody
GTR18222119ERBB2/HER2 Antibody
GTR18222105ERBB2/HER2 Antibody
GTR18082548-01HER2 Antibody / ErbB2
GTR18081154-01HER2 Antibody ErbB2
GTR18574508HER2 Antibody / ErbB2
GTR18795974-01ERBB2 Biosimilar Antibody
GTR18795970-01ERBB2 Biosimilar Antibody

Alternative Products

CatalogName
70R-17127ERBB2 antibody

Popular Products